Takeda San Francisco signs research agreement with the University of California, San Francisco
Do you know when to trade TKPHF ?
TKPHF | Quote | Chart | News | PowerRating -- Takeda San Francisco, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, has entered into a sponsored research collaboration with the University of California, San Francisco. Both the partners are based in the US.
Under the agreement, the research program will focus on therapeutic antibody discovery and development to an undisclosed target. Charles Craik would serve as the principal investigator for the project.
Takeda Pharmaceutical is a Japan-based pharmaceutical company.
Deal Type Partnership
Sub-Category Research and discovery,Development
Deal Status Announced: 2009-09-21
Deal Participants
Partner 1 (Company) Takeda Pharmaceutical Company Limited
Partner 2 (Company) Takeda San Francisco, Inc.
Partner 3 (Company) The University of California, San Francisco
Deal Rationale
The agreement enhances TSF's initiative to build a robust preclinical antibody therapeutics pipeline by leveraging its comprehensive and proprietary antibody technology platform and novel discovery, optimization and development technologies.
For full details on (TKPHF) TKPHF. (TKPHF) has Short Term PowerRatings at TradingMarkets. Details on (TKPHF) Short Term PowerRatings is available at This Link.
- Research and Markets: Takeda Pharmaceutical Company Limited - Company PicShot - 03/19/10
- Takeda withdraws European marketing authorization application for diabetes drug - 03/19/10
- Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met(R) and Actos(R) - 03/16/10
- Ranbaxy Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation - 03/15/10
- Watson Pharmaceuticals settles patent litigation with Takeda Pharmaceutical for Actos(R) - 03/10/10
- More News >>


